Amarin (AMRN) President and CEO Aaron Berg Sells $52K of Stock

On June 26, 2026, Aaron Berg, President and CEO of Amarin Corporation plc, sold 3,197 shares of the company at an average price of $16.35, totaling $52,270.95. This transaction was not part of a planned trading program and reflects recent insider activity at Amarin.

Other Institutional Activity in Amarin

Several institutional investors have recently adjusted their holdings in Amarin Corporation. Sarissa Capital Management LP held its position steady with 1,673,395 shares valued at approximately $24.2 million. Acadian Asset Management LLC increased its stake by 56,327 shares, ending up with 636,769 shares worth about $9.2 million, a 9.7% increase. Kynam Capital Management, LP also grew its holdings by 83,109 shares, resulting in a total of 472,382 shares valued at $6.8 million, marking a 21.3% rise. Millennium Management LLC made a significant increase of 134,301 shares, bringing its total to 300,536 shares worth roughly $4.3 million, an 80.8% boost. On the other hand, Morgan Stanley trimmed its position by 36,937 shares, ending with 293,172 shares valued at $4.2 million, reflecting an 11.2% decrease.

Amarin Corporation plc Stock Up 16.8%

Shares of NasdaqCM:AMRN traded near $15.92 on Wednesday. Amarin Corporation plc has a market cap of approximately $334.2 million and a forward P/E ratio of 16.27. The stock's beta is 0.825, indicating lower volatility compared to the market. Over the past 52 weeks, the stock has ranged from a low of $12.96 to a high of $20.90. Its 50-day moving average is $14.77, while the 200-day moving average is $15.42. The company maintains a healthy current ratio of 3.49 and a quick ratio of 2.32, though its debt-to-equity ratio stands at 1.71.

Recent Earnings

Amarin reported revenue of $216.8 million, showing a modest growth of 7.4%. However, the company faced a net margin of -15.51% and a return on equity of -7.28%, indicating profitability challenges. The next earnings report is expected on July 29, 2026.

Insider Buying and Selling at Amarin Corporation plc

In addition to Aaron Berg's sale, he also acquired 6,250 shares on the same day, indicating mixed insider activity. Patrice Eadon Bonfiglio also engaged in transactions, selling 403 shares at $14.98 on April 18, 2026, and purchasing 838 shares earlier that day.

Analysts Set New Price Targets

Goldman Sachs maintained its 'sell' rating for Amarin on June 25, 2025, with a price target of $12.00. The consensus among analysts suggests a target mean price of $12.50, with two analyst opinions currently available.

About Amarin Corporation

Amarin Corporation plc is a pharmaceutical company based in Dublin, Ireland. It focuses on developing and commercializing therapies for cardiovascular diseases. Its flagship product, VASCEPA, is an omega-3 fatty acid used to reduce triglyceride levels in adults with severe hypertriglyceridemia. The company operates in the United States, Europe, and internationally, working with partners like Mochida Pharmaceutical Co., Ltd. Amarin was founded in 1989 and employs approximately 80 people.

Bottom Line

Aaron Berg's recent sale of Amarin shares adds to the ongoing insider and institutional activity around the company. Investors often monitor such transactions for signals about company performance. However, it's important to remember that these reports are historical and may not reflect current positions or future intentions.